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Caveolin-1 in mesangial cells suppresses MAP kinase activation
and cell proliferation induced by bFGF and PDGF
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Caveolin-1 in mesangial cells suppresses MAP kinase activation
and cell proliferation induced by bFGF and PDGF.
Background. Caveolin is a principal component of caveo-
lae and regulates signaling in caveolae. Mesangial cells contain
many caveolae, and thus manipulation of caveolin-1 expression
level might be useful to control mesangial cell proliferation,
which is an important aggravating factor in many renal diseases.
Methods. In the present study, we transfected caveolin-1
cDNA to rat primary mesangial cells and MES13 cells, and ex-
amined the effects on Raf-extracellular signal-regulated pro-
tein kinase (ERK) kinase (MEK)-mitogen-activated protein
(MAP) kinase pathway and cell proliferation stimulated by ba-
sic fibroblast growth factor (bFGF) and platelet-derived growth
factor (PDGF). Activity of the kinases was analyzed by im-
munofluorescence labeling and Western blot analysis.
Results. The overexpression of caveolin-1 inhibited the acti-
vation of Raf-1, MEK-1/2, and MAP kinase induced by either
bFGF or PDGF. Furthermore, it suppressed the cell prolifer-
ation caused by the cytokines. The effect was specific to the
Raf-MEK-MAP kinase pathway, because it did not influence
activation of Smad2 induced by transforming growth factor-b
(TGF-b). On the contrary, expression of a dominant-negative
caveolin mutant, DGV-caveolin, augmented activation of MAP
kinase.
Conclusion. The result showed that overexpression of
caveolin-1 in mesangial cells suppresses MAP kinase activa-
tion and cell proliferation induced by bFGF and PDGF. Be-
cause bFGF and PDGF are two major cytokines involved in
the mesangioproliferative nephritis, the result implies that in-
troduction of caveolin-1 expression vector is a potential thera-
peutic tool for the disease.
Mesangial cells have a potent ability to proliferate,
causing lesions in a variety of glomerular diseases [1]. Se-
vere disruption of the mesangium and following mesan-
gial proliferation are seen as features of many human
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renal diseases, including IgA nephropathy, membra-
noproliferative glomerulonephritis, necrotizing cres-
centic glomerulonephritis, and allograft rejection [2].
Activation of p42/44 mitogen-activated protein (MAP)
kinase plays a major role in mesangial cell proliferation
both in vitro and in vivo [3–5]. Consistent with this, in
an animal model of experimental mesangioproliferative
glomerulonephritis (Thy 1 nephritis), mesangial cell pro-
liferation was inhibited by a pharmacologic inhibitor of
the extracellular signal-regulated protein kinase (ERK)-
activating kinase in vivo [6]. Among many cytokines that
are involved in mesangial cell proliferation, basic fibrob-
last growth factor (bFGF) and platelet-derived growth
factor (PDGF) have been thought to be main cytokines
in Thy 1 nephritis [7–9]. In fact, mesangial cell prolifer-
ation in Thy 1 nephritis was suppressed by intravenous
injection of neutralizing anti-bFGF and anti-PDGF anti-
body in vivo [10, 11].
Caveolae are membrane invaginations of 50 to 80 nm
in diameter, enriched in free cholesterol, and are thought
to play important roles in cell signaling, endocytosis, and
intracellular cholesterol transport (for reviews, see [12–
14]). Caveolin, a 22 kD integral membrane protein, is a
principal component of caveolae and important for for-
mation of caveolae invagination [15] and functions of
caveolae [13, 14]. The caveolin family consists of caveolin-
1, -2, -3, and their isoforms; caveolin-1 and caveolin-2
are coexpressed and form a hetero-oligomeric complex
in many cell types, whereas caveolin-3 is expressed mainly
in the muscle. Caveolin-1 was the first molecule cloned in
the caveolin family and has been most examined about
functions in cell signaling, endocytosis, and intracellular
cholesterol transport. Receptors of several hormones and
growth factors, and signaling molecules are located in
caveolae, and caveolin-1 modifies their functions [13, 14].
Most importantly, the activation of p42/44 MAP kinase
by the Ras-Raf pathway is inhibited by caveolin-1 [16,
17]. Probably due to the inhibitory function of caveolin-1,
overexpression of caveolin-1 suppresses cell proliferation
in NIH 3T3 fibroblasts and human breast cancer cells [18,
19].
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Caveolin-1 is expressed in rat mesangial cells and in-
creases its expression in Thy 1 nephritis [20], suggest-
ing that caveolin-1 may be involved in mesangioprolif-
erative glomerulonephritis. In this work, we aimed to
examine whether manipulation of caveolin-1 expression
causes any effect on mesangial cells stimulated with bFGF
and PDGF. Because effect of caveolin-1 expression could
be variable depending on the cell type, it was impera-
tive to study on the mesangial cell [21]. As a result, we
found that overexpression of caveolin-1 suppresses ac-
tivation of Raf-1, ERK kinase (MEK)-1/2, and p42/44
MAP kinase, and also reduces proliferation of mesangial
cells. The effect of caveolin-1 on the PDGF pathway has
been reported in other cell types [22], but suppression
of bFGF signaling has not been shown to date. Because
bFGF and PDGF are two major cytokines involved in the
mesangioproliferative nephritis [7–9], the present result
would have important implications in terms of the disease
control.
METHODS
Antibodies and vectors
Recombinant human bFGF and human PDGF BB
(Austral Biologicals, San Ramon, CA, USA) and recom-
binant human transforming growth factor-b1 (TGF-b)
(R&D Systems, Minneapolis, MN, USA) were pur-
chased from respective suppliers. Rabbit polyclonal
anticaveolin-1 antibody (sc-894), rabbit anti-Raf-1 an-
tibody, and rabbit anti-MEK-1 antibody were pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). Rabbit antiphospho-p44/42 MAP kinase
(Thr202/Tyr204), anti-p44/42 MAP kinase antibodies,
antiphospho-Raf-1 antibody (Ser259), and phospho-
MEK-1/2 (Ser217/221) were obtained from Cell Signaling
Technology (Beverly, MA, USA). Mouse monoclonal
anticaveolin-1 antibody (clone 2297) (BD Transduc-
tion Laboratories, Lexington, KY, USA), mouse anti-
HA antibody (12CA5) (Boehringer-Mannheim Corp.,
Indianapolis, IN, USA), anti-Smad2 antibody (Zymed
Laboratories, San Francisco, CA, USA), antiphospho-
Smad2 antibody (Upstate Biotechnology, Lake Placid,
NY, USA), fluorescein-conjugated donkey antimouse
and antirabbit IgG antibodies (Jackson ImmunoRe-
search Lab., West Grove, PA, USA), horseradish perox-
idase (HRP)-conjugated goat antimouse and antirabbit
IgG antibodies (Amersham Biosciences, Piscataway, NJ,
USA) were obtained from respective suppliers. pcDNA
3.1(+) and pEGFP-N1 vectors were purchased from In-
vitrogen (Carlsbad, CA, USA) and Clontech (Palo Alto,
CA, USA), respectively.
Mesangial cell culture
Glomerular cells were cultured from explants of
adult Wistar rat kidneys using standard techniques [23].
The cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Sigma Chemical Co., St. Louis, MO,
USA) supplemented with 20% heat-inactivated fetal
bovine serum (FBS), 100 U/mL penicillin (Invitrogen),
and 100 lg/mL streptomycin (Invitrogen). Identity of the
cells was confirmed by their typical stellate form, by pos-
itive immunostaining for characteristic cytoskeletal pro-
teins (desmin and a-actin), cell surface antigens (Thy 1,
thrombospondin), and by the lack of the leukocyte com-
mon antigen OX-1 or factor VIII [24]. SV40 MES13 cells
(MES13 cells) were purchased from the American Type
Culture Collection (Rockville, MD, USA) and cultured
in DMEM supplemented with 10% heat-inactivated FBS
and antibiotics. Primary mesangial cells of passages 4
through 8 and MES13 cells between passages 30 and 40
were used for the experiments. Where appropriate, cells
were rendered quiescent in DMEM containing no serum
for 24 hours prior to stimulation.
Plasmids, transfection, and generation of stable cell lines
Human caveolin-1a and caveolin-1b cDNAs tagged
with the HA epitope (YPYDVPDYA) at the C-terminus
(caveolin-1a-HA and caveolin-1b-HA) were inserted to
the pcDNA3.1(+) vector. For caveolin-1b , the codon
for the second methionine at position 32 in the endoge-
nous caveolin-1 cDNA was altered as described previ-
ously [25], so that the expression vector gave rise to
only caveolin-1b isoform. Transfection of cDNAs was
performed by LipofectAMINE PLUS (Invitrogen) and
LipofectAMINE 2000 (Invitrogen) according to the man-
ufacturer’s instruction. For primary mesangial cells, non-
transfected cells and those transfected with pEGFP were
used as controls. Dominant-negative caveolin mutant,
DGV-caveolin [26], was cloned by reverse transcriptiom-
polymerase chain reaction (RT-PCR) from mouse muscle
total RNA, sequenced, and inserted to the pEGFP-N1
vector. To establish stable MES13 cell lines overexpress-
ing HA-caveolin-1a and HA-caveolin-1b , transfectants
were selected for resistance to 800 lg/mL G418. Af-
ter three cycles of trypsinization and antibiotic treat-
ment, positive clones were isolated by limited dilution.
Two clones transfected with the same cDNA, survived
the G418 selection, but failed to express HA-caveolin-
1, were used as controls. Because they were kept in the
same G418-containing medium as the positive clones,
they served as good controls. The two clones gave equiv-
alent results; results obtained by one of them (clone 8)
are presented below.
Immunofluorescence microscopy and quantification
of fluorescence intensity
Cells were fixed in freshly-prepared 3% formaldehyde
in phosphate-buffered saline (PBS) for 10 minutes, per-
meabilized with 0.1% Triton X-100 in PBS containing
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10 mmol/L glycine (PBS-G) for 5 minutes. After incu-
bation in PBS-G containing 3% bovine serum albumin
(BSA) for 10 minutes, the cells were incubated with pri-
mary antibodies for 1 hour, and then with the secondary
antibodies conjugated to a fluorochrome for 1 hour. Pho-
tomicrographs were taken by Zeiss Axiophot2 equipped
with Zeiss AxioCam, and exported to Adobe PhotoShop
6.0. Cells to be measured were circumscribed, and the av-
erage fluorescence intensity in a cell was obtained by the
scale of 256 brightness steps using the image histogram
of the software.
Western blot analysis
The protein content was determined by bicinchoninic
acd (BCA) assay [27] using BSA as a standard. Cell
lysate samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) in 10%
or 15% acrylamide gels and electrotransferred to a ni-
trocellulose membrane. The membranes were blocked
for 1 hour in PBS containing 0.1% Tween-20 (PBS-T)
and 5% dried milk, and incubated for 1 hour with a pri-
mary antibody. The membranes were further incubated
with an HRP-conjugated secondary antibody for 1 hour,
and the reaction was visualized using SuperSignal West
Dura Extended Duration Substrate (Pierce, Rockford,
IL, USA) and exposed to Hyperfilm ECL (Amersham
Biosciences).
Measurement of cell proliferation
Rat primary mesangial cells (5 × 105 cells) were plated
in a 35 mm dish. They were transfected with a cDNA
24 hours after plating, and cultured for another 24 hours.
MES13 cells (5 × 105 cells) were plated in a 100 mm dish
and cultured for 24 hours. Both rat primary mesangial
cells and MES13 cells were then cultured in a serum-
free medium for 24 hours, and stimulated by 10 ng/mL
bFGF or PDGF. To measure the cell proliferation, cells
were rinsed 5 times in PBS and trypsinized extensively;
the total number of cells in a dish was counted using a
hemocytometer.
Statistical analysis
To compare quantitative data, an unpaired, two-tailed
Student t test was used. Differences were considered sta-
tistically significant when the P value was less than 0.05.
All values are expressed as mean ± SEM, unless other-
wise stated.
RESULTS
Immunofluorescence microscopy of caveolin-1
in mesangial cells
Immunofluorescence labeling for caveolin-1 was ob-
served as a collection of small dots in rat primary mesan-
A B
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Rat primary mesangial cells MES13 cells
Fig. 1. Endogenous caveolin-1 is labeled by anti-caveolin-1 antibody
in rat primary mesangial cells (A) and MES13 cells (B). Caveolin-1 is
frequently seen densely along the cell edge. HA-caveolin-1 was intro-
duced by transient transfection of cDNA to rat primary mesangial cells
(C) and by stable transfection to MES13 cells (D); it was labeled by
anti-HA antibody, and was found distributed in a similar pattern as
endogenous caveolin-1 (bars, 10 lm).
gial cells and MES13 cells. They were often found in
patches or in linear arrays, and frequently seen along
the cell edges (Fig. 1A and B). In primary rat mesangial
cells, transiently transfected with HA-caveolin-1 cDNA,
the labeling for HA was seen in the same manner as en-
dogenous caveolin-1 (Fig. 1C); caveolin-1a and caveolin-
1b showed similar distribution. By the present protocol,
HA-caveolin-1 was expressed in 20% to 40% of the cells
2 days after transfection. The distribution in MES13 sta-
bly expressing HA-caveolin-1 was also observed in the
same manner (Fig. 1D). Colocalization of endogenous
caveolin-1 and HA-caveolin-1 was confirmed by double
immunolabeling (data not shown).
Western blot analysis of caveolin-1 in mesangial cells
Expression of endogenous caveolin-1 and transfected
HA-caveolin-1 was analyzed by Western blotting. Ex-
pression of HA-caveolin-1a and b in transfected cells was
confirmed by anti-HA antibody (Fig. 2A, upper panel);
by anti-caveolin-1 antibody, the upper band of caveolin-
1a, and the lower band of caveolin-1b was seen to be-
come intense by the expression of HA-caveolin-1a or
HA-caveolin-1b , respectively (Fig. 2A, lower panel). By
the present method of electrophoresis, the addition of
HA sequence (9 amino acids; formula molecular weight
is 1101.2) did not cause a visible mobility shift and only
made the bands thicker. The stably transfected MES13
cells showed similar results (Fig. 2B). The reason is not
clear, but only the upper a isoform was detected in
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anti-caveolin-1
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Lane 1 : control
Lane 2 : EGFP-transfected
Lane 3 : HA-caveolin-1α-transfected
Lane 4 : HA-caveolin-1β-transfected
Lane 1 : control
Lane 2 : sham-transfected (clone 8)
Lane 3 : HA-caveolin-1α-transfected
Lane 4 : HA-caveolin-1β-transfected
A B Fig. 2. Rat primary mesangial cells (A) and
MES13 cells (B). The same amount of cell
lysates were electrophoresed. Transfected
HA-caveolin-1 was detected by anti-HA (up-
per panel), and total caveolin-1 (i.e., summa-
tion of endogenous and transfected caveolin-
1) was probed by anticaveolin-1 (lower panel).
The reaction with anti-HA antibody is seen
only in transfected cell samples, and the
amount of total caveolin-1, either the a or b
isoform, in transfected cells was apparently
more abundant than in control nontransfected
cells or in cells transfected with an unrelated
plasmid.
MES13 cells expressing HA-caveolin-1a, and only the
lower b isoform was seen in the cell expressing HA-
caveolin-1b . We previously showed that caveolin-1a and
1b are derived from distinct mRNAs [28], and may not
be generated by alternative translation initiation as had
been believed. Thus in MES13 cells, there may be a mech-
anism that overexpression of a caveolin-1 isoform re-
presses transcription of the other isoform.
Suppression of bFGF-and PDGF-stimulated kinase
activity by overexpression of caveolin-1
Effect of caveolin-1 overexpression was analyzed
by immunofluorescence microscopy and Western blot-
ting utilizing antiphospho-p42/44 MAP kinase antibody,
which recognizes p42/44 MAP kinase only when acti-
vated. By immunofluorescence microscopy, labeling for
phospho-p42/44 MAP kinase was negligible in nonstimu-
lated mesangial cells (Fig. 3A). In rat primary mesangial
cells expressing EGFP, virtually all the cells showed in-
tense labeling after stimulation by either 10 ng/mL bFGF
or 10 ng/mL PDGF for 15 minutes (Fig. 3B and C). On
the other hand, when cells were transfected with either
HA-caveolin-1a or HA-caveolin-1b cDNA, the cells that
express HA-caveolin-1 showed significantly less labeling
for phospho-p42/44 MAP kinase than the adjacent cells
without HA labeling. The result was similar whether cells
were stimulated with bFGF (Fig. 3B) or PDGF (Fig. 3C),
and whether HA-caveolin-1a or HA-caveolin-1b was ex-
pressed.
The fluorescence intensity of the phospho-p42/44 MAP
kinase labeling was quantified as described in the Meth-
ods section, and the relative ratio between nonstimulated
and ligand-stimulated cells was compared. The cells ex-
pressing HA-caveolin-1 were selected from acquired im-
ages, and the fluorescence labeling for phospho-p42/44
MAP kinase was incorporated using the same setting with
a minimum possible bias. The result shows that the rela-
tive increase of the fluorescence, reflecting the amount
of activated p42/44 MAP kinase caused by the ligand
stimulation, was significantly less in cells expressing HA-
caveolin-1a or HA-caveolin-1b , compared to those ex-
pressing no HA-caveolin-1 or expressing EGFP alone
(Fig. 4).
The degree of p42/44 MAP kinase activation was also
compared between nontransfected and transfected cells
by Western blotting. In control rat primary mesangial
cells, reaction for phospho-p42/44 MAP kinase was in-
tensified drastically by stimulation with either bFGF or
PDGF according to the above protocol (Fig. 5A, upper
panel); bands of both 42 and 44 kD became strongly posi-
tive. In cells expressing HA-caveolin-1a or HA-caveolin-
1b , the degree of activation was far less compared to the
controls, although the reaction for phospho-p42/44 MAP
kinase was intensified by the ligand stimulation. The to-
tal amount of p42/44 MAP kinase was equivalent among
different samples (Fig. 5A, lower panel). The effect of
caveolin-1 overexpression on p42/44 MAP kinase activa-
tion was similar in MES13 cells (Fig. 5B), although dif-
ference between nontransfected and transfected cell lines
was less evident compared to that of primary mesangial
cells.
To examine whether overexpression of caveolin-1 sup-
presses other components of the Raf-MEK-MAP kinase
pathway, effect on activation of Raf-1 and MEK-1/2 was
also analyzed by Western blotting of rat primary mesan-
gial cells. By overexpression of either HA-caveolin-1a
or HA-caveolin-1b , phosphorylation of Raf-1 and MEK-
1/2 caused by bFGF or PDGF was markedly suppressed
(Fig. 5C). The result indicates that caveolin-1 could down-
regulate multiple targets in the Raf-MEK-MAP kinase
pathway in the mesangial cell. To verify that the effect
of caveolin-1 is specific to signaling in caveolae, and not
due to nonspecific influence on cell function, activation
of Smad2 caused by TGF-b was also examined. Signal-
ing of the TGF-b-Smad2 pathway in the mesangial cell is
thought to occur in noncaveolar domain of the plasma
membrane [20]. Under the same experimental condi-
tion, overexpression of either HA-caveolin-1a or HA-
caveolin-1b did not change the degree of phosphorylation
of Smad2 (Fig. 5D), indicating that the effect of caveolin-
1 is specific to signaling in caveolae and caveolae-like
membrane.
The effect on MAP kinase was further controlled by us-
ing a dominant-negative caveolin-mutant, DGV-caveolin
[26]. The molecule is an amino-terminal truncated cave-
olin mutant, and was shown to disrupt the cholesterol-rich
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Fig. 4. Rat primary mesangial cells, non-
stimulated or stimulated with basic fibrob-
last growth factor (bFGF) or platelet-derived
growth factor (PDGF), were labeled for
phospho-mitogen-activated protein (MAP)
kinase. Its labeling intensity was quantified as
described in the Methods section. For trans-
fected samples, only cells expressing the intro-
duced proteins were selected, and the reaction
intensity by the anti-phospho-MAP kinase an-
tibody was measured. The relative ratio of
reaction intensity (i.e., stimulated vs. non-
stimulated cells) is shown. (A) bFGF stimu-
lation. (B) PDGF stimulation. The increase
of phospho-MAP kinase labeling was sup-
pressed significantly in cells expressing HA-
caveolin-1a or HA-caveolin-1b (P < 0.01).
The result of EGFP-transfected cells was
equivalent to nontransfected control cells.
microdomain by perturbing intracellular cholesterol traf-
ficking. As expected, MAP kinase activation by bFGF or
PDGF was augmented by transfection of DGV-caveolin
cDNA in rat primary mesangial cells (Fig. 5E). The result
corroborates the conjecture that caveolin-1 inhibits MAP
kinase in a specific manner.
Suppression of bFGF- and PDGF-stimulated cell prolif-
eration by overexpression of caveolin-1
The above result on activation of p42/44 MAP ki-
nase suggested that mesangial cell proliferation caused
by bFGF and PDGF may also be suppressed by overex-
pression of caveolin-1. To examine this, the rate of cell
proliferation after stimulation with bFGF or PDGF was
compared among controls, cells overexpressing caveolin-
1, and cells transfected with DGV-caveolin in rat primary
mesangial cells, and between controls and cells overex-
pressing caveolin-1 in MES13 cells, according to the pro-
tocol in Figure 6A. In rat primary mesangial cells, the cell
number in each group was equivalent up to 72 hours af-
ter seeding; but upon stimulation with 10 ng/mL bFGF
or 10 ng/mL PDGF, the increase of cell number during
the next 24 hours was significantly less in cells express-
ing either HA-caveolin-1a or HA-caveolin-1b compared
to nontransfected or EGFP-expressing cells. For cells
transfected with DGV-caveolin, no significant differ-
ence was seen from non-transfected or EGFP-expressing
cells (Fig. 6B). Similarly, in MES13 cells, expression of
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 3. Effect of caveolin-1 overexpression on p42/44 mitogen-activated protein (MAP) kinase activation was assessed by double labeling of HA-
caveolin-1 and phospho-MAP kinase. Rat primary mesangial cell were doubly labeled by anti-HA and anti-phospho-MAP kinase antibodies (bars
10 lm). (A) Control, nonstimulated cells. Cells (arrows) do not express HA-caveolin-1 (left) and are hardly labeled by anti-phospho-MAP kinase
antibody (right). (B and C) Cells were transfected with cDNA of either EGFP (left panel), HA-caveolin-1a (middle panel), or HA-caveolin-1b (right
panel), and stimulated for 15 minutes with 10 ng/mL basic fibroblast growth factor (bFGF) (B) or platelet-derived growth factor (PDGF) (C). The
upper panel shows distribution of EGFP or HA-caveolin-1, and the lower panel shows labeling of phospho-MAP kinase. Cells expressing exogenous
proteins and adjacent nontransfected cells are marked by arrows and arrowheads, respectively. In (B) and (C), the fluorescence intensity of green
fluorescent protein (GFP) and the antiphospho-MAP kinase labeling was not correlated (left panel). In contrast, the intensity of antiphospho-MAP
kinase labeling was significantly less in cells expressing HA-caveolin-1a (middle panel) or HA-caveolin-1b (right panel) compared to nontransfected
cells. EGFP, enhanced green fluorescent protein.
HA-caveolin-1 did not affect the rate of proliferation
up to 48 hours after seeding. When stimulated with
bFGF or PDGF, however, either HA-caveolin-1a or HA-
caveolin-1b suppressed the increase of cell number sig-
nificantly (Fig. 6C). The result shows that overexpression
of caveolin-1 suppresses mesangial cell proliferation in-
duced by bFGF and PDGF.
DISCUSSION
Mesangial cell proliferation caused by cytokines is a
common feature of many renal diseases [1, 2, 8], and a
means to control mesangial cell proliferation could be a
therapy for renal diseases. A recent report showed that
mitogenic stimuli cause reduction of the caveolin-1 ex-
pression in rat mesangial cells [20]. Because caveolin-1
is known to suppress many pathways of signal transduc-
tion [13, 14], it is reasonable to assume that an increase of
the expression level of caveolin-1 may reduce mesangial
cell proliferation. Thus, in the present study, we examined
consequences of caveolin-1 overexpression in mesangial
cells by transfecting caveolin-1 cDNA. We used rat pri-
mary mesangial cells and a mouse mesangial cell line,
MES13 cells. In both cell lines, caveolin-1 overexpression
inhibited activation of Raf-1, MEK-1/2, and MAP kinase,
caused by bFGF or by PDGF; furthermore, the procedure
suppressed subsequent cell proliferation. The above re-
sult was not due to some non-specific effect of caveolin-
1 overexpression, because TGF-b–dependent activation
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Fig. 5. Effect of caveolin-1 overexpression. Activation of signaling molecules after stimulation for 15 minutes with 10 ng/mL basic fibroblast growth
factor (bFGF) or 10 ng/mL platelet-derived growth factor (PDGF) (A, C, and E), or with 10 ng/mL transforming growth factor-b (TGF-b) (D) were
estimated by Western blotting. (A) Mitogen-activated protein (MAP) kinase in the rat primary mesangial cell. In control and EGFP-expressing
cells, the reaction intensity with antiphospho-MAP kinase increased markedly. In contrast, in cells expressing HA-caveolin-1a or HA-caveolin-1b ,
the increase after the stimulation was less significant. The amount of p42/44 MAP kinase was equivalent in different samples as shown by the
reaction with anti-MAP kinase. (B) MAP kinase in MES13 cells. bFGF stimulation (left panel). PDGF stimulation (right panel). Compared to
nontransfected control cells and sham-transfected cells (clone 8), cells expressing HA-caveolin-1a or HA-caveolin-1b showed less activation of
p42/44 MAP kinase, when stimulated with either bFGF or PDGF. The amount of total p42/44 MAP kinase was equivalent in different samples. (C)
Raf-1 and MEK in the rat primary mesangial cell. The reaction intensity with both antiphospho-Raf-1 and antiphospho-MEK-1/2 after stimulation
was suppressed in cells expressing HA-caveolin compared to the controls. The amount of Raf-1 and MEK-1 was equivalent in different samples.
(D) Smad2 in the rat primary mesangial cell. The increase of the reaction intensity with antiphospho-Smad2 stimulated after TGF-b stimulation
was not different between controls and cells expressing HA-caveolin-1a or HA-caveolin-1b . (E) Effect of DGV-caveolin on MAP kinase in the rat
primary mesangial cell. The expression of the dominant-negative caveolin increased phosphorylation of MAP kinase after stimulation compared
to controls.
of Smad2, which is thought to occur in the noncaveolar
membrane in the mesangial cell [20], was not affected by
the procedure. The suppressive effect of caveolin-1 on
cell proliferation has been reported repeatedly in onco-
genically transformed cells and established cell lines [16–
19]. But its effect in cells in primary culture has been
scarce. The present result with the primary mesangial
cells in early passages is important because it indicates
that caveolin-1 could exert a similar suppressive function
in normal untransformed cells.
Previous reports showed that overexpression of
caveolin-1 inhibits activation of PDGF receptor and
its down-stream signal transduction [22]. On the other
hand, effect of caveolin-1 on FGF receptors and their
downstream signaling pathway has not been defined
clearly. Four distinct FGF receptors have been discov-
ered (FGFR1, FGFR2, FGFR3, and FGFR4) [29, 30],
and in the rat renal glomerulus, FGFR1, FGFR2, and
FGFR3 have been reported to exist [31]. Signaling stim-
ulated by bFGF was shown to occur in a caveolae-like
membrane [32], and FGF receptors bound by bFGF is
endocytosed through caveolae [33]. Moreover, all FGF
receptors have the caveolin-1-binding motif [29, 30, 34].
We demonstrated for the first time that the p42/44 MAP
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Fig. 6. Time course of the experiment to es-
timate the effect of caveolin-1 overexpression
on mesangial cell proliferation. (A) Details
are described in the Methods section. (B) The
relative increase of cells during 24 hours after
ligand stimulation. The number of cells before
stimulation, that is, up to 72 hours for rat pri-
mary mesangial cells and up to 48 hours for
MES13 cells, was equivalent in control and
caveolin-1-overexpressing cells. The cell pro-
liferation after stimulation is shown as a rela-
tive increase of cell number (i.e., cell number
24 hours after stimulation divided by that be-
fore stimulation). Expression of EGFP in rat
primary mesangial cells or sham-transfection
in MES13 cells (clone 8) did not affect the
cell increase. In contrast, expression of HA-
caveolin-1a or HA-caveolin-1b suppressed
cell proliferation induced by either basic fi-
broblast growth factor (bFGF) or platelet-
derived growth factor (PDGF) in both cell
types (P < 0.01).
kinase-mediated signaling and cell proliferation induced
by bFGF stimulation can be suppressed by overexpres-
sion of caveolin-1. This is particularly important in ex-
ploring a method to control mesangial cell proliferation
because bFGF is thought to be a major cytokine along
with PDGF involved in the mesangioproliferative nephri-
tis [7–9].
The mechanism that caveolin-1 inhibits signaling is
not necessarily clear at present. Direct interaction of
caveolin-1 and signaling molecules (e.g., Raf-1, MEK1/2,
and p42/44 MAP kinase) by the so-called caveolin-1 scaf-
folding domain is one possibility [34]; reduction of the
upstream Raf-1 and MEK1/2 activity should also sup-
press p42/44 MAP kinase indirectly. On top of that, it has
been proposed that caveolin-1 exerts the effect by influ-
encing the plasmalemmal cholesterol concentration and
the integrity of microdomains [26]. These possibilities are
not exclusive each other, and both may work simultane-
ously. In the present study, expression of DGV-caveolin
augmented activation of MAP kinase induced by PDGF
or bFGF. Because DGV-caveolin is thought to exert the
dominant-negative effect by depleting cholesterol in the
plasma membrane [26], it is reasonable to assume that
the suppressive effect of caveolin-1 on the MAP kinase
pathway in the mesangial cell is due at least partly to its
cholesterol transport function [35]. On the other hand,
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despite activation of MAP kinase by DGV-caveolin, the
proliferation of primary mesangial cells did not change
significantly. It might appear contradictory, but is thought
to result from adverse effects of DGV-caveolin on other
signaling molecules [26].
Considering many important functions that had been
ascribed to caveolae and caveolin-1, no increase of tu-
mors in caveolin-1-null mouse was a surprise [36, 37].
Moreover, even concerning the influence on cell prolifer-
ation, an increase of caveolin-1 production is associated
with metastasis in breast and prostate cancers [38]. There-
fore it is now supposed that a change of caveolin-1 level
could exert variable effects depending on the cellular con-
text [21]. Because of these complexities, it is imperative
to study the specific cell type to understand the effect
of caveolin-1 overexpression. We showed that an artifi-
cial introduction of caveolin-1 is inhibitory to prolifera-
tion of the mesangial cell. But due to the complexities of
caveolin-1 function, there is a good reason to be cautious
in using the same treatment in other cell types.
Mesangial cells have a potent ability of proliferation,
and their proliferation is observed in a variety of renal
diseases [1, 2]. Importance of mesangial cells in the patho-
genesis has been clearly exemplified in Thy 1 nephritis, in
which severe disruption of the mesangium and mesangial
cell proliferation, resembling human mesangioprolifer-
ative glomerulonephritis, are observed [39]. Many cy-
tokines appear to be involved in the mesangial cell
proliferation [9], but bFGF and PDGF are thought to be
most important in animal model of mesangioproliferative
nephritis, Thy 1 nephritis [7, 8, 10, 11]. In fact, intravenous
injection of neutralizing anti-bFGF and anti-PDGF
antibodies suppressed the cell proliferation considerably
[10, 11]. In the downstream of stimulation by cytokines,
activation of p42/44 MAP kinase is important for cell pro-
liferation in Thy 1 nephritis [6].
CONCLUSION
We demonstrated that caveolin-1 overexpression in
mesangial cells could suppress activation of not only
p42/44 MAP kinase, but also its upstream molecules, Raf-
1 and MEK-1/2 induced either by bFGF or by PDGF. Fur-
thermore, cell proliferation caused by the cytokines were
suppressed significantly. This demonstrates that caveolin-
1 could inhibit two major mitogen-induced pathways in
Thy 1 nephritis. The next experimental step is to exam-
ine whether the same measure can be used as a ther-
apy in living animals. In rats, cDNA can be transfected
selectively to mesangial cells by electroporation; PDGF
receptor-IgG chimera gene transfer was shown to ame-
liorate mesangioproliferative glomerulonephritis [40]. It
is interesting to study whether introduction of caveolin-1
by electroporation could inhibit mesangial cell prolifera-
tion in Thy 1 nephritis effectively. If the result turns out
to be positive, caveolin-1 overexpression by an expres-
sion vector might be also used as a therapy for human
glomerular diseases.
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